These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38341324)

  • 1. SOHO State of the Art Updates and Next Questions | Diagnosis, Outcomes, and Management of Prefibrotic Myelofibrosis.
    Vachhani P; Loghavi S; Bose P
    Clin Lymphoma Myeloma Leuk; 2024 Jul; 24(7):413-426. PubMed ID: 38341324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical features and next-generation sequencing landscape of essential thrombocythemia, prefibrotic primary myelofibrosis, and overt fibrotic primary myelofibrosis: a Chinese monocentric retrospective study.
    Zhang L; Ye X; Luo S; Xu X; Wang S; Jin K; Zheng Y; Zhu X; Chen D; Jin J; Huang J
    J Cancer Res Clin Oncol; 2023 Jun; 149(6):2383-2392. PubMed ID: 35731275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis and management of prefibrotic myelofibrosis.
    Rumi E; Sant'Antonio E; Boveri E; Pietra D; Cavalloni C; Roncoroni E; Astori C; Arcaini L;
    Expert Rev Hematol; 2018 Jul; 11(7):537-545. PubMed ID: 29862872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early/prefibrotic primary myelofibrosis in patients who were initially diagnosed with essential thrombocythemia.
    Kamiunten A; Shide K; Kameda T; Ito M; Sekine M; Kubuki Y; Hidaka T; Akizuki K; Tahira Y; Toyama T; Kawano N; Marutsuka K; Maeda K; Takeuchi M; Kawano H; Sato S; Ishizaki J; Shimoda H; Yamashita K; Matsuoka H; Shimoda K
    Int J Hematol; 2018 Oct; 108(4):411-415. PubMed ID: 29987745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
    Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
    Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia.
    Barbui T; Thiele J; Vannucchi AM; Tefferi A
    Leukemia; 2013 Oct; 27(10):1953-8. PubMed ID: 23467025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.
    Barbui T; Thiele J; Passamonti F; Rumi E; Boveri E; Ruggeri M; Rodeghiero F; d'Amore ES; Randi ML; Bertozzi I; Marino F; Vannucchi AM; Antonioli E; Carrai V; Gisslinger H; Buxhofer-Ausch V; Müllauer L; Carobbio A; Gianatti A; Gangat N; Hanson CA; Tefferi A
    J Clin Oncol; 2011 Aug; 29(23):3179-84. PubMed ID: 21747083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Features, Gene Alterations, and Outcomes in Prefibrotic and Overt Primary and Secondary Myelofibrotic Patients.
    Kim TY; Kwag D; Lee JH; Lee J; Min GJ; Park SS; Park S; Jeon YW; Yoon JH; Shin SH; Yahng SA; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Cho SG; Lee JW; Lee JM; Kim M; Lee SE
    Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The morphology features of bone marrow in the prefibrotic-early primary myelofibrosis].
    Gong XB; Zhang XH; Lu XG; Tang QS; Gao X; Yang J
    Zhonghua Xue Ye Xue Za Zhi; 2012 Jan; 33(1):25-30. PubMed ID: 22575188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A lasso and random forest model using flow cytometry data identifies primary myelofibrosis.
    Zhang F; Wang YZ; Chang Y; Yuan XY; Shi WH; Shi HX; Shen JZ; Liu YR
    Cytometry B Clin Cytom; 2024 Jul; 106(4):272-281. PubMed ID: 38647185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and molecular features of patients with prefibrotic primary myelofibrosis previously diagnosed as having essential thrombocythemia in Japan.
    Edahiro Y; Araki M; Inano T; Ito M; Morishita S; Misawa K; Fukuda Y; Imai M; Ohsaka A; Komatsu N
    Eur J Haematol; 2019 Jun; 102(6):516-520. PubMed ID: 30977935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombosis in essential thrombocytemia and early/prefibrotic primary myelofibrosis: the role of the WHO histological diagnosis.
    Rupoli S; Goteri G; Picardi P; Micucci G; Canafoglia L; Scortechini AR; Federici I; Giantomassi F; Da Lio L; Zizzi A; Honorati E; Leoni P
    Diagn Pathol; 2015 Apr; 10():29. PubMed ID: 25885405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-omics differences in the bone marrow between essential thrombocythemia and prefibrotic primary myelofibrosis.
    Zhang A; Sun T; Yu D; Fu R; Liu X; Xue F; Liu W; Ju M; Dai X; Dong H; Gu W; Chen J; Chi Y; Li H; Wang W; Yang R; Chen Y; Zhang L
    Clin Exp Med; 2024 Jul; 24(1):154. PubMed ID: 38972952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GATA1 downregulation in prefibrotic and fibrotic stages of primary myelofibrosis and in the myelofibrotic progression of other myeloproliferative neoplasms.
    Sangiorgio VFI; Nam A; Chen Z; Orazi A; Tam W
    Leuk Res; 2021 Jan; 100():106495. PubMed ID: 33360878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis.
    Guglielmelli P; Pacilli A; Rotunno G; Rumi E; Rosti V; Delaini F; Maffioli M; Fanelli T; Pancrazzi A; Pietra D; Salmoiraghi S; Mannarelli C; Franci A; Paoli C; Rambaldi A; Passamonti F; Barosi G; Barbui T; Cazzola M; Vannucchi AM;
    Blood; 2017 Jun; 129(24):3227-3236. PubMed ID: 28351937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Clinical and Molecular Features Between Patients With Essential Thrombocythemia and Early/Prefibrotic Primary Myelofibrosis Presenting With Thrombocytosis in Taiwan.
    Kuo MC; Chuang WY; Chang H; Lin TH; Wu JH; Lin TL; Ou CW; Hung YS; Huang TY; Huang YJ; Wang PN; Shih LY
    Am J Clin Pathol; 2023 May; 159(5):474-483. PubMed ID: 36857745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis.
    Barbui T; Thiele J; Carobbio A; Passamonti F; Rumi E; Randi ML; Bertozzi I; Vannucchi AM; Gisslinger H; Gisslinger B; Finazzi G; Ruggeri M; Rodeghiero F; Rambaldi A; Gangat N; Tefferi A
    Blood; 2012 Jul; 120(3):569-71. PubMed ID: 22700720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms.
    Mora B; Passamonti F
    Curr Hematol Malig Rep; 2022 Oct; 17(5):127-139. PubMed ID: 36048275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review.
    Kc D; Falchi L; Verstovsek S
    Ann Hematol; 2017 Oct; 96(10):1595-1604. PubMed ID: 28808761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2016 Dec; 91(12):1262-1271. PubMed ID: 27870387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.